Nov 29, 2018 7:00am EST Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes
Nov 9, 2018 7:30am EST Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights
Nov 6, 2018 7:00am EST Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 “HONOR” Study in Poster Presentation at CNS Summit 2018
Nov 1, 2018 7:00am EDT Tonix Pharmaceuticals to Present at BIO-Europe International Partnering Conference
Oct 31, 2018 7:00am EDT Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya® for PTSD, Following FDA Meeting
Oct 29, 2018 7:00am EDT Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in Poster Presentations at CNS Summit 2018
Oct 23, 2018 7:00am EDT Tonix Pharmaceuticals to Present at the Dawson James Securities Small Cap Growth Conference
